<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-39306" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Infliximab-abda</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aboobacker</surname>
            <given-names>Shamma</given-names>
          </name>
          <aff>Al Arif Heart &#x00026; Children Medical Centre</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Aboud</surname>
            <given-names>Ahmad M.</given-names>
          </name>
          <aff>King Abdullah Medical City</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shamma Aboobacker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmad Al Aboud declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-39306.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Infliximab (IFX) is a biologic agent that specifically targets an immune mediator, tumor necrosis factor alpha (TNFa), involved in a pathological process. Anti TNFa agents have enjoyed use as therapeutic modalities since 1998; however, their first use in dermatology dates back to 2002 when they first saw use in the treatment of psoriasis. FDA-Approved indications include Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. This activity describes the mode of action of infliximab-abda, including adverse event profiles, and other key factors e.g. dosing, pharmacodynamics, pharmacokinetics, monitoring, and highlights the role of the interprofessional team in the management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of infliximab-abda.</p></list-item><list-item><p>Describe the adverse effects of infliximab-abda.</p></list-item><list-item><p>Review appropriate monitoring and toxicity management of infliximab-abda.</p></list-item><list-item><p>Summarize complications of infliximab-abda and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=39306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=39306">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-39306.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Infliximab (IFX)&#x000a0;is a biologic agent that specifically targets an immune mediator, tumor necrosis factor alpha (TNFa), involved in a pathological process. Anti&#x000a0;TNFa&#x000a0;agents have enjoyed use as therapeutic modalities since 1998; however, their first use in dermatology dates back to 2002 when they first saw use in the treatment of psoriasis.<xref ref-type="bibr" rid="article-39306.r1">[1]</xref> The first anti-TNF therapy was discovered by Knight et al. in the form of a chimeric monoclonal antibody, now known as infliximab, comprising a 25-30% murine fusion or antigen-binding variable segment and a 70-75% human IgG antibody constant segment.<xref ref-type="bibr" rid="article-39306.r2">[2]</xref>. The first trial of IFX was carried out in 1994 on patients with rheumatoid arthritis in whom IFX resulted in marked clinical improvement compared with placebo.<xref ref-type="bibr" rid="article-39306.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved indications<xref ref-type="bibr" rid="article-39306.r4">[4]</xref>:</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Crohn disease including pediatric Crohn disease</p>
          </list-item>
          <list-item>
            <p>Ulcerative colitis including pediatric ulcerative colitis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Plaque psoriasis</p>
          </list-item>
          <list-item>
            <p>Juvenile idiopathic arthritis</p>
          </list-item>
        </list>
        <p>Crohn disease&#x000a0;&#x02013;&#x000a0;Moderately to severely active Crohn disease is an indication for induction and maintenance of clinical remission</p>
        <p>An inadequate response to conventional therapy holds as an indication for starting infliximab in such cases.</p>
        <p>Pediatric cases aged six years or older with moderate-to-severe disease that fails to respond to conventional therapy are indications for infliximab.&#x000a0;</p>
        <p>Ulcerative colitis&#x000a0;&#x02013;&#x000a0;Infliximab is prescribed for inducing and maintaining clinical remission and for eliminating corticosteroid therapy in those showing inadequate response.</p>
        <p>Pediatric cases 6 years and older are suitable for this mode of treatment.</p>
        <p>Rheumatoid arthritis - Patients undergoing infliximab therapy for moderate-to-severe disease have reported inhibition of progressing joint damage and improved&#x000a0;physical strength.</p>
        <p>Psoriasis&#x000a0;&#x02013;&#x000a0;The following types of&#x000a0;psoriasis benefit from infliximab therapy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic plaque psoriasis or stable psoriasis of moderate-to-severe involvement</p>
          </list-item>
          <list-item>
            <p>Recalcitrant psoriasis</p>
          </list-item>
          <list-item>
            <p>Unstable psoriasis</p>
          </list-item>
          <list-item>
            <p>Generalized pustular psoriasis or von Zumbusch pustular psoriasis</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-label uses<xref ref-type="bibr" rid="article-39306.r5">[5]</xref>:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic diseases &#x02013;
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus associated glomerulonephritis</p></list-item><list-item><p>Systemic sclerosis</p></list-item><list-item><p>Dermatomyositis</p></list-item><list-item><p>Sjogren&#x02019;s syndrome</p></list-item><list-item><p>Adult-onset Still disease</p></list-item><list-item><p>Granulomatosis with polyangiitis</p></list-item><list-item><p>Giant cell arteritis</p></list-item><list-item><p>Sarcoidosis</p></list-item><list-item><p>Organ-specific autoimmune disease</p></list-item><list-item><p>Diabetes type 1</p></list-item><list-item><p>Autoimmune inner ear disease</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Ocular diseases &#x02013;
<list list-type="bullet"><list-item><p>Idiopathic uveitis or scleritis</p></list-item><list-item><p>Birdshot retinochoroiditis</p></list-item><list-item><p>Grave&#x02019;s disease ophthalmopathy</p></list-item><list-item><p>Idiopathic scleritis</p></list-item><list-item><p>Cystoid macular edema (uveitic and diabetic)</p></list-item><list-item><p>Age-related macular degeneration</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Dermatological diseases &#x02013;
<list list-type="bullet"><list-item><p>Pemphigoid</p></list-item><list-item><p>Hidradenitis suppurative</p></list-item><list-item><p>Pyoderma gangrenosum</p></list-item><list-item><p>Acne</p></list-item><list-item><p>Aphthous stomatitis</p></list-item><list-item><p>Subcorneal pustular dermatosis</p></list-item><list-item><p>Atopic dermatitis</p></list-item><list-item><p>Toxic epidermal necrolysis</p></list-item><list-item><p>Behcet&#x02019;s syndrome</p></list-item><list-item><p>SAPHO syndrome</p></list-item><list-item><p>Pityriasis rubra pilaris</p></list-item><list-item><p>Eosinophilic fasciitis</p></list-item><list-item><p>Panniculitis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other &#x02013;
<list list-type="bullet"><list-item><p>Chronic obstructive pulmonary disease</p></list-item><list-item><p>Polymyalgia rheumatica</p></list-item><list-item><p>Idiopathic membranous nephropathy</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-39306.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Infliximab, being a TNFa inhibitor, acts by blocking TNFa, which is a proinflammatory pleiotropic cytokine particularly involved in defense mechanisms. Nevertheless, the role of TNFa differs respectively to its concentration as low levels confer a protective effect while high amounts display a pathogenic role.<xref ref-type="bibr" rid="article-39306.r6">[6]</xref>&#x000a0;TNFa exists in two forms; soluble and transmembrane, that is both biologically active via TNF receptors (TNFR) Type 1 and Type 2.<xref ref-type="bibr" rid="article-39306.r7">[7]</xref></p>
        <p>The protective role in infection is the most important effect of TNFa. Interestingly,&#x000a0;TNFa is involved in attaining resistance to infectious agents, as well as having a pathogenic role in septic shock. TNFa produces anti-inflammatory effects by signaling via TNFR Type 2. The explanation has been that TNFa promotes resistance by activation of polymorphonuclear leucocytes and platelets, while enhancing the cytotoxic action of macrophages and natural killer cells, and thereby&#x000a0;stimulation of the immune system.<xref ref-type="bibr" rid="article-39306.r8">[8]</xref> In particular, studying the concept on patients with meningococcal disease showed high levels of TNFa in the serum that coincided with its cytotoxic effect.<xref ref-type="bibr" rid="article-39306.r9">[9]</xref><xref ref-type="bibr" rid="article-39306.r10">[10]</xref></p>
        <p>Another role of TNFa is resistance to tumors and occurs due to the cytotoxic effect of TNFa leading to cell lysis or apoptosis. Fiers studied the effect of TNFa on tumors in animal models and found that TNFa acts directly on the tumor cells, particularly in the presence of interferon.<xref ref-type="bibr" rid="article-39306.r11">[11]</xref> Additionally, TNFa has been determined to exert proinflammatory effects on the vascular endothelium that results in hemorrhagic necrosis.<xref ref-type="bibr" rid="article-39306.r7">[7]</xref></p>
        <p>In particular, the biological effects are beneficial in a variety of host responses. However,&#x000a0;TNFa has been found to exert pathogenic roles in certain instances.</p>
        <p>The role of&#x000a0;TNFa&#x000a0;in inflammatory diseases was identified in 1988 with the finding of increased TNFa expression in synovial fluid of patients with rheumatoid arthritis making it the prototypic disease of TNFa. This finding obtained confirmation with the discovery of increased TNFR expression in active diseases. Furthermore, the quantities of shed receptors correlate with the disease activity. The evidence suggests that TNFa acts as a regulator of proinflammatory cytokines and therefore, has a central role in inflammatory processes.<xref ref-type="bibr" rid="article-39306.r12">[12]</xref></p>
        <p>Another disease linked with TNFa is psoriasis. Studies have shown increased expression of TNFa in psoriatic skin lesions. The study confirmed this by investigating the peripheral blood mononuclear cells for the presence of TNFa mRNA expression and revealed increased expression in psoriatic patients when compared to healthy controls.<xref ref-type="bibr" rid="article-39306.r7">[7]</xref><xref ref-type="bibr" rid="article-39306.r13">[13]</xref></p>
        <p>Infliximab acts by binding to both soluble and membrane-bound forms of TNF, the binding with TNFa&#x000a0;is found to be stable with high affinity, thereby&#x000a0;neutralizing its action; In addition, it causes apoptosis of cells that release TNFa, alters the cytokine secretion and up regulates p38 MAP kinase which takes part in the downward signaling of TNFa. Binding triggers intracellular signaling, complement-mediated cell lysis and decrease of cytokine production.<xref ref-type="bibr" rid="article-39306.r14">[14]</xref></p>
        <p>The effect of intracellular signaling launches a variety of responses including reduction of cytokines<xref ref-type="bibr" rid="article-39306.r15">[15]</xref>, an increase in vascular permeability,<xref ref-type="bibr" rid="article-39306.r16">[16]</xref> a decrease in adhesion molecule expression, and inactivation of cell lines.<xref ref-type="bibr" rid="article-39306.r17">[17]</xref> Another response is the delayed recruitment of immune cells to sites of inflammation, however, this excludes the regulatory T-cells that play a beneficial role in immune responses and leads to its increased expression.<xref ref-type="bibr" rid="article-39306.r18">[18]</xref><xref ref-type="bibr" rid="article-39306.r19">[19]</xref><xref ref-type="bibr" rid="article-39306.r20">[20]</xref></p>
      </sec>
      <sec id="article-39306.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Prior to infliximab infusion, pretreatment with loratadine or cetirizine (0.5 mg/kg; max 25 mg), hydrocortisone (4 mg/kg; max 200 mg) and paracetamol (15 mg/kg; max 1 gm) 30&#x000a0;&#x02013;&#x000a0;60 minutes before infusion is necessary for combating infusion reactions that may occur.<xref ref-type="bibr" rid="article-39306.r21">[21]</xref></p>
        <p>Infliximab is prepared as an intravenous infusion the dosage of which can vary from 3 to 10 mg/kg, most commonly being 5 mg/kg. Infliximab has a half-life&#x000a0;of 7-12 days as it has a low rate of elimination. Therefore, dosing schedule repeats at weeks 2, 6 and every eight weeks thereafter.<xref ref-type="bibr" rid="article-39306.r22">[22]</xref></p>
        <p>The pharmaceutical product contains 100 mg lyophilized drug powder in 20 ml vial. Each vial is reconstituted with 10 ml sterile distilled water using a 21-gauge needle following which gentle stirring&#x000a0;is performed to dissolve the powder. The vial is kept aside for 5 mins, and the solution dissolved in 250 ml of 0.9% sodium chloride intravenous solution.<xref ref-type="bibr" rid="article-39306.r23">[23]</xref></p>
        <p>Infusion of this agent should begin within 3 hours of dilution and over a period or 2-3 hours during which period the recording of vitals including temperature, pulse, blood pressure, and respiratory rate is required until 1-hour post infusion.&#x000a0;</p>
        <p>FDA-approved indications with dosages<xref ref-type="bibr" rid="article-39306.r24">[24]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriasis and Psoriatic arthritis&#x000a0;&#x02013;&#x000a0;5 mg/kg at weeks 0, 2 and 6 followed by every 8 weeks.</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis&#x000a0;&#x02013;&#x000a0;3 mg/kg at 0, 2 and 6 weeks followed by every 8 wks. According to response, the dose may be incremented up to 10 mg/kg and spaced at every four weeks.</p>
          </list-item>
          <list-item>
            <p>Ankylosing Spondylitis&#x000a0;&#x02013;&#x000a0;5 mg/kg at weeks 0,2 and 6 followed by every 6 - 8 weeks.</p>
          </list-item>
          <list-item>
            <p>Crohn&#x02019;s disease and Ulcerative colitis&#x000a0;&#x02013;&#x000a0;5 mg/kg at 0, 2 and six weeks and subsequently every eight weeks. Doses may be escalated up to 10 mg/kg depending upon response.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-39306.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Infectious risk<xref ref-type="bibr" rid="article-39306.r25">[25]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Deep mycosis such as histoplasmosis, coccidioidomycosis, blastomycosis, aspergillosis, candidiasis</p>
          </list-item>
          <list-item>
            <p>Listeriosis and pneumocystosis</p>
          </list-item>
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Abscess</p>
          </list-item>
          <list-item>
            <p>Cellulitis</p>
          </list-item>
          <list-item>
            <p>Skin ulcers</p>
          </list-item>
          <list-item>
            <p>Pyelonephritis</p>
          </list-item>
        </list>
        <p>
<bold>Infusion reactions<xref ref-type="bibr" rid="article-39306.r26">[26]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate
<list list-type="bullet"><list-item><p>Anaphylaxis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Delayed
<list list-type="bullet"><list-item><p>Myalgia</p></list-item><list-item><p>Arthralgia</p></list-item><list-item><p>Fever and Chills</p></list-item><list-item><p>Pruritus</p></list-item><list-item><p>Edema</p></list-item><list-item><p>Urticaria and flushing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dysphagia</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Dyspepsia</p>
          </list-item>
        </list>
        <p>
<bold>Other</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sore throat</p>
          </list-item>
          <list-item>
            <p>Flu-like syndrome</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Vertigo</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Lupus-like syndrome</p>
          </list-item>
          <list-item>
            <p>Serum sickness</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Demyelinating disease</p>
          </list-item>
          <list-item>
            <p>Lymphoma and other malignancies&#x000a0;&#x02013;hepatospleenic T-cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Cytopenias</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-39306.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The absolute contraindications for the use of biologics are:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of&#x000a0;active infections, more&#x000a0;importantly, latent or active tuberculosis, Hepatitis B, C and HIV and</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to murine products or infliximab</p>
          </list-item>
        </list>
        <p>Other contraindications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>PUVA sessions</p>
          </list-item>
          <list-item>
            <p>Premalignant conditions</p>
          </list-item>
          <list-item>
            <p>Demyelinating disease (Guillain-Barre syndrome)</p>
          </list-item>
          <list-item>
            <p>Optic neuritis</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Pregnancy and lactation</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Jaundice or marked liver enzyme elevations</p>
          </list-item>
          <list-item>
            <p>Stricturing disease<xref ref-type="bibr" rid="article-39306.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-39306.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Baseline Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count and hemogram</p>
          </list-item>
          <list-item>
            <p>Erythrocyte sedimentation rate or C-reactive protein</p>
          </list-item>
          <list-item>
            <p>Liver function test</p>
          </list-item>
          <list-item>
            <p>Renal function test and urinalysis</p>
          </list-item>
          <list-item>
            <p>Serum electrolytes</p>
          </list-item>
          <list-item>
            <p>Anti-nuclear and anti-dsDNA antibodies</p>
          </list-item>
          <list-item>
            <p>Screening for hepatitis and HIV infection</p>
          </list-item>
          <list-item>
            <p>Chest X-ray</p>
          </list-item>
          <list-item>
            <p>Tuberculin skin testing or interferon-gamma release assay test</p>
          </list-item>
          <list-item>
            <p>Pregnancy test in females of childbearing age</p>
          </list-item>
          <list-item>
            <p>If indicated&#x000a0;&#x02013;&#x000a0;serology for varicella zoster and measles.&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Ongoing Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Evaluation of response to treatment can is measurable by respective assessment scores, i.e., Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), PCDAI, PUCAI at three months initially and subsequently every six months.</p>
          </list-item>
          <list-item>
            <p>Complete blood count and hemogram repeated at three months and every six monthly thereafter&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Liver function test, Renal function test, serum electrolytes, and urinalysis undergo evaluation at three months and every six months.<xref ref-type="bibr" rid="article-39306.r27">[27]</xref><xref ref-type="bibr" rid="article-39306.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-39306.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overuse of infliximab results in long-term inhibition of TNFa and thereby&#x000a0;enhances the risk of infections, which furthermore poses deleterious effects for pregnancy and lactation by impairing newborn&#x02019;s defense mechanisms.</p>
        <p>Since TNFa is involved in embryogenesis and organogenesis, a deleterious effect on embryo and fetal development is postulated.</p>
        <p>Another toxic effect of infliximab is the carcinogenic potential resulting from reports of malignancies in children, adolescents, and young adults receiving infliximab over a median value of 30 sessions. This hypothesis comes from the finding that TNFa causes tumoral hemorrhagic necrosis and therefore used as a treatment for selective tumors.<xref ref-type="bibr" rid="article-39306.r29">[29]</xref></p>
      </sec>
      <sec id="article-39306.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The primary drawback with biologic therapy is the necessity for life-long or long-term treatment, the failure of which can lead to incomplete resolution or recurrences. Combination with other agents such as methotrexate can enhance the efficacy and response.<xref ref-type="bibr" rid="article-39306.r30">[30]</xref></p>
        <p>Live vaccines and contact with infectious agents should be avoided during infliximab therapy due to the markedly depressed immunity that can result in disseminated infections.<xref ref-type="bibr" rid="article-39306.r31">[31]</xref>&#x000a0;History of latent or active tuberculosis with no confirmation of complete therapy or recent travel to a country with a high incidence of tuberculosis may warrant a course of empiric anti-tubercular therapy. Avoidance of concomitant therapy with anakinra and abatacept is important due to the increased risk of severe infections.<xref ref-type="bibr" rid="article-39306.r32">[32]</xref></p>
      </sec>
      <sec id="article-39306.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=39306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=39306">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/39306/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=39306">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-39306.s11">
        <title>References</title>
        <ref id="article-39306.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordoro</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>TNF-alpha inhibitors in dermatology.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>4</fpage>
            <page-range>4-6</page-range>
            <pub-id pub-id-type="pmid">17940711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knight</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shealy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McDonough</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scallon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vilcek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daddona</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.</article-title>
            <source>Mol Immunol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>16</issue>
            <fpage>1443</fpage>
            <page-range>1443-53</page-range>
            <pub-id pub-id-type="pmid">8232330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maini</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Kalden</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Macfarlane</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Antoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leeb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Woody</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Schaible</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>1552</fpage>
            <page-range>1552-63</page-range>
            <pub-id pub-id-type="pmid">9751087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steeland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Libert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vandenbroucke</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>A New Venue of TNF Targeting.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>May</month>
            <day>11</day>
            <volume>19</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">29751683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sfikakis</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.</article-title>
            <source>Curr Dir Autoimmun</source>
            <year>2010</year>
            <volume>11</volume>
            <fpage>180</fpage>
            <page-range>180-210</page-range>
            <pub-id pub-id-type="pmid">20173395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tracey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sasso</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Salfeld</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.</article-title>
            <source>Pharmacol Ther</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-79</page-range>
            <pub-id pub-id-type="pmid">18155297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schottelius</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Moldawer</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Dinarello</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Asadullah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Biology of tumor necrosis factor-alpha- implications for psoriasis.</article-title>
            <source>Exp Dermatol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>193</fpage>
            <page-range>193-222</page-range>
            <pub-id pub-id-type="pmid">15086336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ziring</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Korin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gjertson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>TNFalpha blockade in human diseases: mechanisms and future directions.</article-title>
            <source>Clin Immunol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-36</page-range>
            <pub-id pub-id-type="pmid">17916444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esposito</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cuzzocrea</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma.</article-title>
            <source>Curr Med Chem</source>
            <year>2009</year>
            <volume>16</volume>
            <issue>24</issue>
            <fpage>3152</fpage>
            <page-range>3152-67</page-range>
            <pub-id pub-id-type="pmid">19689289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halstensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Espevik</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.</article-title>
            <source>Lancet</source>
            <year>1987</year>
            <month>Feb</month>
            <day>14</day>
            <volume>1</volume>
            <issue>8529</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">2880163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiers</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level.</article-title>
            <source>FEBS Lett</source>
            <year>1991</year>
            <month>Jul</month>
            <day>22</day>
            <volume>285</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-212</page-range>
            <pub-id pub-id-type="pmid">1649771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Development of anti-TNF therapy for rheumatoid arthritis.</article-title>
            <source>Nat Rev Immunol</source>
            <year>2002</year>
            <month>May</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>364</fpage>
            <page-range>364-71</page-range>
            <pub-id pub-id-type="pmid">12033742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uyemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fivenson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Modlin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nickoloff</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response.</article-title>
            <source>J Invest Dermatol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>701</fpage>
            <page-range>701-5</page-range>
            <pub-id pub-id-type="pmid">7693825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitoma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Horiuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of action of anti-TNF-&#x003b1; agents - Comparison among therapeutic TNF-&#x003b1; antagonists.</article-title>
            <source>Cytokine</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>101</volume>
            <fpage>56</fpage>
            <page-range>56-63</page-range>
            <pub-id pub-id-type="pmid">27567553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalden</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Antoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Eberl</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>deWoody</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maini</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.</article-title>
            <source>J Immunol</source>
            <year>1999</year>
            <month>Aug</month>
            <day>01</day>
            <volume>163</volume>
            <issue>3</issue>
            <fpage>1521</fpage>
            <page-range>1521-8</page-range>
            <pub-id pub-id-type="pmid">10415055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scaldaferri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sgambato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rutella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cittadini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piqu&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Panes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiocchi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.</article-title>
            <source>J Immunol</source>
            <year>2006</year>
            <month>Feb</month>
            <day>15</day>
            <volume>176</volume>
            <issue>4</issue>
            <fpage>2617</fpage>
            <page-range>2617-24</page-range>
            <pub-id pub-id-type="pmid">16456024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritchlin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Haas-Smith</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.</article-title>
            <source>J Clin Invest</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>821</fpage>
            <page-range>821-31</page-range>
            <pub-id pub-id-type="pmid">12639988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Souto-Carneiro</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mahadevan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fritsch-Stork</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nanki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldbach-Mansky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2009</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>R84</fpage>
            <pub-id pub-id-type="pmid">19500335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leipe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skapenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Schulze-Koops</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Regulatory T cells in rheumatoid arthritis.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2005</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>93</fpage>
            <pub-id pub-id-type="pmid">15899057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lacroix-Desmazes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kazatchkine</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kaveri</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?</article-title>
            <source>Nat Rev Immunol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>1p following 86; author reply 1p following 86</fpage>
            <pub-id pub-id-type="pmid">18049489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wasserman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bykerk</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.</article-title>
            <source>J Rheumatol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>1912</fpage>
            <page-range>1912-7</page-range>
            <pub-id pub-id-type="pmid">15468353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mital</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biologics use in Indian psoriasis patients.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>489</fpage>
            <page-range>489-497</page-range>
            <pub-id pub-id-type="pmid">27990383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Feagan</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rachmilewitz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
              <collab>ACCENT I Study Group</collab>
            </person-group>
            <article-title>Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>May</month>
            <day>04</day>
            <volume>359</volume>
            <issue>9317</issue>
            <fpage>1541</fpage>
            <page-range>1541-9</page-range>
            <pub-id pub-id-type="pmid">12047962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monaco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nanchahal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF therapy: past, present and future.</article-title>
            <source>Int Immunol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-62</page-range>
            <pub-id pub-id-type="pmid">25411043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aygun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adrovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barut</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cokugras</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Camc&#x00131;oglu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kasapcopur</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.</article-title>
            <source>Clin Rheumatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>1025</fpage>
            <page-range>1025-1030</page-range>
            <pub-id pub-id-type="pmid">30448935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerbleski</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Dermatological complications and safety of anti-TNF treatments.</article-title>
            <source>Gut</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>1033</fpage>
            <page-range>1033-9</page-range>
            <pub-id pub-id-type="pmid">19592682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Archer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hock</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Essat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poku</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clowes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pandor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.</article-title>
            <source>Health Technol Assess</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>66</issue>
            <fpage>1</fpage>
            <page-range>1-294</page-range>
            <pub-id pub-id-type="pmid">30501821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geborek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saxne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bendtzen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1828</fpage>
            <page-range>1828-34</page-range>
            <pub-id pub-id-type="pmid">18032541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Safety of tumour necrosis factor-alpha antagonists.</article-title>
            <source>Drug Saf</source>
            <year>2004</year>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-24</page-range>
            <pub-id pub-id-type="pmid">15061685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kerdel</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis.</article-title>
            <source>Arch Dermatol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>139</volume>
            <issue>7</issue>
            <fpage>949</fpage>
            <page-range>949-50</page-range>
            <pub-id pub-id-type="pmid">12873907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heller</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Murase</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>870</fpage>
            <pub-id pub-id-type="pmid">21920245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-39306.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salliot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">18203761</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
